Recognizing and managing asymptomatic left ventricular dysfunction after myocardial infarction.
Albert
Nancy M
NM
George M. and Linda H. Kaufman Center for Heart Failure, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA. albertn@ccf.org
Lewis
Connie
C
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D003422:Critical Care / Q000379:methods*; D019091:Critical Pathways; D017147:Defibrillators, Implantable; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D000451:Mineralocorticoid Receptor Antagonists; D009203:Myocardial Infarction / Q000150:complications*; D009720:Nurse Clinicians / Q000458:organization & administration; D024802:Nurse's Role; D009730:Nursing Assessment / Q000379:methods; D010348:Patient Care Team / Q000458:organization & administration; D010351:Patient Discharge; D010353:Patient Education as Topic; D017410:Practice Guidelines as Topic; D011379:Prognosis; D018570:Risk Assessment; D012307:Risk Factors; D014481:United States / Q000453:epidemiology; D018487:Ventricular Dysfunction, Left / Q000175:diagnosis* / Q000453:epidemiology / Q000209:etiology / Q000628:therapy*
D000319:Adrenergic beta-Antagonists; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000451:Mineralocorticoid Receptor Antagonists